Johnson & Johnson completed the acquisition of V-Wave for $1.7bn.

Johnson & Johnson, an American multinational pharmaceutical, biotechnology, and medical technologies corporation, completed the acquisition of V-Wave, a privately-held company focused on developing innovative treatment options for patients with heart failure, for $1.7bn. “At V-Wave, we are dedicated to achieving our vision to help patients around the world – and we know Johnson & Johnson MedTech shares this mission. We are confident that Johnson & Johnson MedTech is well-positioned to ensure V-Wave’s breakthrough ideas and technology reach patients in need as quickly and effectively as possible. I couldn’t be prouder of the V-Wave team, and the commitment it has taken to achieve this milestone. We look forward to continuing to build a world where cardiovascular disease is prevented, treated, and cured,” Dr. Neal Eigler, V-Wave CEO.